| Year |
Citation |
Score |
| 2021 |
Pascual T, Oliveira M, Villagrasa P, Ortega V, Paré L, Bermejo B, Morales S, Amillano K, López R, Galván P, Canes J, Salvador F, Nuciforo P, Rubio IT, Llombart-Cussac A, ... ... Baselga J, et al. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Npj Breast Cancer. 7: 145. PMID 34824288 DOI: 10.1038/s41523-021-00351-4 |
0.368 |
|
| 2021 |
Smyth LM, Batist G, Meric-Bernstam F, Kabos P, Spanggaard I, Lluch A, Jhaveri K, Varga A, Wong A, Schram AM, Ambrose H, Carr TH, de Bruin EC, Salinas-Souza C, Foxley A, ... ... Baselga J, et al. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer. Npj Breast Cancer. 7: 44. PMID 33863913 DOI: 10.1038/s41523-021-00251-7 |
0.39 |
|
| 2020 |
Arruabarrena-Aristorena A, Maag JLV, Kittane S, Cai Y, Karthaus WR, Ladewig E, Park J, Kannan S, Ferrando L, Cocco E, Ho SY, Tan DS, Sallaku M, Wu F, Acevedo B, ... ... Baselga J, et al. FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer. Cancer Cell. PMID 32888433 DOI: 10.1016/J.Ccell.2020.08.003 |
0.357 |
|
| 2020 |
Xu J, Higgins MJ, Tolaney SM, Come SE, Smith MR, Fornier M, Mahmood U, Baselga J, Yeap BY, Chabner BA, Isakoff SJ. A phase II trial of cabozantinib in hormone-receptor positive breast cancer with bone metastases. The Oncologist. PMID 32463152 DOI: 10.1634/theoncologist.2020-0127 |
0.33 |
|
| 2020 |
Smyth LM, Tamura K, Oliveira M, Ciruelos EM, Mayer IA, Sablin MP, Biganzoli L, Ambrose HJ, Ashton J, Barnicle A, Cashell DD, Corcoran C, de Bruin EC, Foxley A, Hauser J, ... ... Baselga J, et al. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With -Mutant, ER-Positive Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32312891 DOI: 10.1158/1078-0432.CCR-19-3953 |
0.395 |
|
| 2020 |
Subbiah V, Puzanov I, Blay JY, Chau I, Lockhart AC, Raje NS, Wolf J, Baselga J, Meric-Bernstam F, Roszik J, Diamond EL, Riely GJ, Sherman EJ, Riehl T, Pitcher B, et al. Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery. PMID 32029534 DOI: 10.1158/2159-8290.CD-19-1265 |
0.359 |
|
| 2020 |
Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, Ferrando L, Selenica P, Ladewig E, Chan C, Da Cruz Paula A, Witkin M, Cheng Y, Park J, Serna-Tamayo C, ... ... Baselga J, et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nature Genetics. PMID 31932695 DOI: 10.1038/S41588-019-0554-0 |
0.322 |
|
| 2020 |
Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, ... ... Baselga J, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery. PMID 31915197 DOI: 10.1158/2159-8290.Cd-19-0116 |
0.381 |
|
| 2019 |
Bines J, Procter M, Restuccia E, Viale G, Zardavas D, Suter T, Arahmani A, Van Dooren V, Baselga J, Clark E, Eng-Wong J, Gelber RD, Piccart M, Mobus V, de Azambuja E, et al. Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Clinical Breast Cancer. PMID 31924513 DOI: 10.1016/j.clbc.2019.06.016 |
0.335 |
|
| 2019 |
Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sorensen M, ... ... Baselga J, et al. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery. PMID 31806627 DOI: 10.1158/2159-8290.Cd-19-0966 |
0.436 |
|
| 2019 |
Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, Xu G, Kazmi A, Chang MT, Taylor BS, Dickler MN, ... ... Baselga J, et al. Double mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science (New York, N.Y.). 366: 714-723. PMID 31699932 DOI: 10.1126/Science.Aaw9032 |
0.322 |
|
| 2019 |
Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Peña L, Nuciforo P, Ballestrero A, Dubsky P, Lombard JM, Vuylsteke P, Castaneda CA, Colleoni M, Santos Borges G, Ciruelos E, ... ... Baselga J, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology. PMID 31402321 DOI: 10.1016/S1470-2045(19)30334-1 |
0.384 |
|
| 2019 |
Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, ... ... Baselga J, et al. Tumour lineage shapes BRCA-mediated phenotypes. Nature. PMID 31292550 DOI: 10.1038/s41586-019-1382-1 |
0.329 |
|
| 2019 |
Di Cosimo S, Triulzi T, Pizzamiglio S, De Cecco L, de Azambuja E, Fumagalli D, Putzai L, Harbeck N, Izquierdo M, Peña L, Daidone MG, Huober J, Gori S, Cinieri S, Torri V, ... Baselga J, et al. The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. European Journal of Cancer (Oxford, England : 1990). 118: 1-9. PMID 31284184 DOI: 10.1016/j.ejca.2019.06.001 |
0.331 |
|
| 2019 |
Rothé F, Silva MJ, Venet D, Campbell C, Bradbury I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa DD, Chia SK, Wardley AM, Ueno T, ... ... Baselga J, et al. Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30862692 DOI: 10.1158/1078-0432.CCR-18-2521 |
0.318 |
|
| 2019 |
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, ... ... Baselga J, et al. Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 1434. PMID 30770493 DOI: 10.1158/1078-0432.CCR-18-4267 |
0.325 |
|
| 2019 |
Sonnenblick A, Bailey A, Uziely B, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Cameron D, Bell R, Zardavas D, Al-Sakaff N, Gelber RD, Dowsett M, Leyland-Jones B, et al. Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. Anticancer Research. 39: 797-802. PMID 30711959 DOI: 10.21873/anticanres.13177 |
0.362 |
|
| 2019 |
Prat A, Brase JC, Cheng Y, Nuciforo P, Paré L, Pascual T, Martínez D, Galván P, Vidal M, Adamo B, Hortobagyi GN, Baselga J, Ciruelos E. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. The Oncologist. PMID 30679318 DOI: 10.1634/theoncologist.2018-0407 |
0.324 |
|
| 2019 |
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, ... ... Baselga J, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics. PMID 30643254 DOI: 10.1038/S41588-018-0312-8 |
0.338 |
|
| 2018 |
Gupta S, Vanderbilt CM, Cotzia P, Arias Stella JA, Chang JC, Zehir A, Benayed R, Nafa K, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME, Ross DS. Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management. The Journal of Molecular Diagnostics : Jmd. PMID 30576871 DOI: 10.1016/J.Jmoldx.2018.10.006 |
0.322 |
|
| 2018 |
Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, et al. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. Jama Oncology. e184475. PMID 30543347 DOI: 10.1001/jamaoncol.2018.4475 |
0.385 |
|
| 2018 |
Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, ... ... Baselga J, et al. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell. 34: 893-905.e8. PMID 30537512 DOI: 10.1016/J.Ccell.2018.11.006 |
0.326 |
|
| 2018 |
Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, ... ... Baselga J, et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. Embo Molecular Medicine. PMID 30377213 DOI: 10.15252/Emmm.201809172 |
0.355 |
|
| 2018 |
Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber RD, et al. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. PMID 30335191 DOI: 10.1002/cncr.31784 |
0.323 |
|
| 2018 |
Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, ... ... Baselga J, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling. 11. PMID 30301790 DOI: 10.1126/Scisignal.Aat9773 |
0.397 |
|
| 2018 |
Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, ... ... Baselga J, et al. p95HER2-T cell bispecific antibody for breast cancer treatment. Science Translational Medicine. 10. PMID 30282693 DOI: 10.1126/scitranslmed.aat1445 |
0.329 |
|
| 2018 |
Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, ... ... Baselga J, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. European Journal of Cancer (Oxford, England : 1990). 103: 147-154. PMID 30241001 DOI: 10.1016/j.ejca.2018.08.002 |
0.35 |
|
| 2018 |
Cruz C, Llop-Guevara A, Garber JE, Arun BK, Pérez Fidalgo JA, Lluch A, Telli ML, Fernández C, Kahatt C, Galmarini CM, Soto-Matos A, Alfaro V, Pérez de la Haza A, Domchek SM, Antolin S, ... ... Baselga J, et al. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018786558. PMID 30240327 DOI: 10.1200/JCO.2018.78.6558 |
0.359 |
|
| 2018 |
Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, ... ... Baselga J, et al. Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017748392. PMID 30235087 DOI: 10.1200/JCO.2017.74.8392 |
0.377 |
|
| 2018 |
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, ... ... Baselga J, et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell. 34: 427-438.e6. PMID 30205045 DOI: 10.1016/J.Ccell.2018.08.008 |
0.363 |
|
| 2018 |
Ross DS, Zehir A, Brogi E, Konno F, Krystel-Whittemore M, Edelweiss M, Berger MF, Toy W, Chandarlapaty S, Razavi P, Baselga J, Wen HY. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 30158597 DOI: 10.1038/S41379-018-0116-5 |
0.4 |
|
| 2018 |
Bielski CM, Zehir A, Penson AV, Donoghue MTA, Chatila W, Armenia J, Chang MT, Schram AM, Jonsson P, Bandlamudi C, Razavi P, Iyer G, Robson ME, Stadler ZK, Schultz N, ... Baselga J, et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics. PMID 30013179 DOI: 10.1038/S41588-018-0165-1 |
0.343 |
|
| 2018 |
Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, ... ... Baselga J, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018779777. PMID 29989854 DOI: 10.1200/Jco.2018.77.9777 |
0.345 |
|
| 2018 |
Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, et al. Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial. Jama Oncology. 4: e181564. PMID 29902299 DOI: 10.1001/jamaoncol.2018.1564 |
0.306 |
|
| 2018 |
Rodon J, Pérez-Fidalgo A, Krop IE, Burris H, Guerrero-Zotano A, Britten CD, Becerra C, Schellens J, Richards DA, Schuler M, Abu-Khalaf M, Johnson FM, Ranson M, Edenfield J, Silva AP, ... ... Baselga J, et al. Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. PMID 29882016 DOI: 10.1007/S00280-018-3610-Z |
0.324 |
|
| 2018 |
Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, ... ... Baselga J, et al. Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. Journal of the National Cancer Institute. PMID 29878225 DOI: 10.1093/jnci/djy094 |
0.371 |
|
| 2018 |
Dickler MN, Saura C, Richards D, Krop I, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, ... Baselga J, et al. Phase II Study of Taselisib (GDC‑0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29793946 DOI: 10.1158/1078-0432.Ccr-18-0613 |
0.329 |
|
| 2018 |
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, ... ... Baselga J, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 554: 189-194. PMID 29420467 DOI: 10.1038/Nature25475 |
0.377 |
|
| 2018 |
Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, ... ... Baselga J, et al. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017727107. PMID 29401002 DOI: 10.1200/Jco.2017.72.7107 |
0.345 |
|
| 2017 |
Chang MT, Shrestha Bhattarai T, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, Chakravarty D, Phillips S, Kandoth C, Penson A, Gorelick A, Shamu T, Patel S, Harris C, Gao J, ... ... Baselga J, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discovery. PMID 29247016 DOI: 10.1158/2159-8290.Cd-17-0321 |
0.343 |
|
| 2017 |
Baselga J, Coleman RE, Cortés J, Janni W. Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology. PMID 29042085 DOI: 10.1016/j.critrevonc.2017.10.001 |
0.366 |
|
| 2017 |
Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, ... ... Baselga J, et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). European Journal of Cancer (Oxford, England : 1990). 85: 133-145. PMID 28923573 DOI: 10.1016/j.ejca.2017.08.020 |
0.393 |
|
| 2017 |
Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, et al. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. Bmc Cancer. 17: 646. PMID 28899363 DOI: 10.1186/S12885-017-3641-6 |
0.301 |
|
| 2017 |
Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, et al. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clinical Breast Cancer. PMID 28830796 DOI: 10.1016/j.clbc.2017.05.006 |
0.35 |
|
| 2017 |
Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology. PMID 28800861 DOI: 10.1016/S1470-2045(17)30450-3 |
0.372 |
|
| 2017 |
Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, ... ... Baselga J, et al. A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Research and Treatment. PMID 28681171 DOI: 10.1007/s10549-017-4375-5 |
0.378 |
|
| 2017 |
Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 28576675 DOI: 10.1016/S1470-2045(17)30376-5 |
0.401 |
|
| 2017 |
Dickler MN, Tolaney S, Rugo HS, Cortés J, Dieras V, Patt DA, Wildiers H, Hudis CA, O'Shaughnessy JA, Zamora E, Yardley D, Frenzel M, Koustenis AG, Baselga J. MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28533223 DOI: 10.1158/1078-0432.CCR-17-0754 |
0.334 |
|
| 2017 |
Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 28526536 DOI: 10.1016/S1470-2045(17)30312-1 |
0.312 |
|
| 2017 |
Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, ... ... Baselga J, et al. AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017730143. PMID 28489509 DOI: 10.1200/Jco.2017.73.0143 |
0.345 |
|
| 2017 |
Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, ... ... Baselga J, et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28381415 DOI: 10.1158/1078-0432.Ccr-16-2287 |
0.381 |
|
| 2017 |
Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA, Baselga J. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. Science (New York, N.Y.). 355: 1324-1330. PMID 28336670 DOI: 10.1126/Science.Aah6893 |
0.341 |
|
| 2017 |
Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, et al. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. PMID 28324268 DOI: 10.1007/s10549-017-4199-3 |
0.39 |
|
| 2017 |
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, et al. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet (London, England). PMID 28215665 DOI: 10.1016/S0140-6736(16)32616-2 |
0.328 |
|
| 2017 |
Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, Yu AF, Argolo D, Smyth LM, Modi S, Schweber S, Boafo C, Patil S, Norton L, Baselga J, et al. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. The Oncologist. PMID 28167568 DOI: 10.1634/Theoncologist.2016-0268 |
0.3 |
|
| 2016 |
Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B, Razavi P, Hyman DM, Baselga J, Berger MF, Ladanyi M, Arcila ME. Next-Generation Assessment of ERBB2 (Human Epidermal Growth Factor Receptor 2) Amplification Status: Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay. The Journal of Molecular Diagnostics : Jmd. PMID 28027945 DOI: 10.1016/J.Jmoldx.2016.09.010 |
0.323 |
|
| 2016 |
Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. The Lancet. Oncology. PMID 27964843 DOI: 10.1016/S1470-2045(16)30631-3 |
0.365 |
|
| 2016 |
Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardy AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, ... ... Baselga J, et al. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports. 17: 2367-2381. PMID 27880910 DOI: 10.1016/J.Celrep.2016.10.077 |
0.363 |
|
| 2016 |
Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, ... ... Baselga J, et al. A First-in-Human Phase I Study of the ATP-Competitive Akt Inhibitor Ipatasertib (GDC-0068) Demonstrates Robust and Safe Targeting of Akt in Patients with Solid Tumors. Cancer Discovery. PMID 27872130 DOI: 10.1158/2159-8290.Cd-16-0512 |
0.306 |
|
| 2016 |
Fumagalli D, Venet D, Ignatiadis M, Azim HA, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, ... ... Baselga J, et al. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. Jama Oncology. PMID 27684533 DOI: 10.1001/jamaoncol.2016.3824 |
0.324 |
|
| 2016 |
Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, ... ... Baselga J, et al. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell. PMID 27641504 DOI: 10.1016/j.cell.2016.08.041 |
0.333 |
|
| 2016 |
Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, Baselga J, Garraway LA. Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discovery. PMID 27604488 DOI: 10.1158/2159-8290.Cd-16-0305 |
0.364 |
|
| 2016 |
Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L, Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, Garcia S, Macías I, Salvador F, ... ... Baselga J, et al. Stratification and therapeutic potential of PML in metastatic breast cancer. Nature Communications. 7: 12595. PMID 27553708 DOI: 10.1038/Ncomms12595 |
0.36 |
|
| 2016 |
Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. Jama Oncology. PMID 27532364 DOI: 10.1001/jamaoncol.2016.1279 |
0.35 |
|
| 2016 |
Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, Baselga J, Cross D, Eyers PA, Alessi DR. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth. The Embo Journal. PMID 27481935 DOI: 10.15252/Embj.201693929 |
0.309 |
|
| 2016 |
Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, Baselga J, Scaltriti M. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer Cell. PMID 27451907 DOI: 10.1016/J.Ccell.2016.06.004 |
0.31 |
|
| 2016 |
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, Baselga J, et al. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Research. PMID 27020857 DOI: 10.1158/0008-5472.Can-15-0728 |
0.357 |
|
| 2016 |
Toska E, Baselga J. Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 2099-101. PMID 26957555 DOI: 10.1158/1078-0432.Ccr-16-0038 |
0.34 |
|
| 2016 |
Ebbesen SH, Scaltriti M, Bialucha CU, Morse N, Kastenhuber ER, Wen HY, Dow LE, Baselga J, Lowe SW. Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America. PMID 26929372 DOI: 10.1073/pnas.1523693113 |
0.366 |
|
| 2016 |
Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino E, Samant M, Olsen S, de Haas S, Pegram MD. Relationship Between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26920887 DOI: 10.1158/1078-0432.CCR-15-2499 |
0.379 |
|
| 2016 |
Scaltriti M, Elkabets M, Baselga J. Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 22: 1313-7. PMID 26763248 DOI: 10.1158/1078-0432.CCR-15-1458 |
0.321 |
|
| 2015 |
Carmona FJ, Montemurro F, Kannan S, Rossi V, Verma C, Baselga J, Scaltriti M. AKT signaling in ERBB2-amplified breast cancer. Pharmacology & Therapeutics. PMID 26645663 DOI: 10.1016/J.Pharmthera.2015.11.013 |
0.374 |
|
| 2015 |
Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, et al. Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26598744 DOI: 10.1200/JCO.2015.62.1797 |
0.358 |
|
| 2015 |
Llombart-Cussac A, Bermejo B, Villanueva C, Delaloge S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, ... ... Baselga J, et al. SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Research and Treatment. 154: 351-7. PMID 26536871 DOI: 10.1007/s10549-015-3616-8 |
0.324 |
|
| 2015 |
Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, ... ... Baselga J, et al. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26503204 DOI: 10.1200/JCO.2014.60.1971 |
0.356 |
|
| 2015 |
Iyengar NM, Fornier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, ... ... Baselga J, et al. A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. Clinical Breast Cancer. PMID 26454612 DOI: 10.1016/J.Clbc.2015.09.009 |
0.321 |
|
| 2015 |
García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, ... ... Baselga J, et al. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26272063 DOI: 10.1158/1078-0432.Ccr-14-3091 |
0.311 |
|
| 2015 |
Salgado R, Denkert C, Campbell C, Savas P, Nucifero P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. Jama Oncology. 1: 448-54. PMID 26181252 DOI: 10.1001/jamaoncol.2015.0830 |
0.37 |
|
| 2015 |
Swain SM, Clark E, Baselga J. Treatment of HER2-positive metastatic breast cancer. The New England Journal of Medicine. 372: 1964-5. PMID 25970056 DOI: 10.1056/NEJMc1503446 |
0.324 |
|
| 2015 |
Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, ... ... Baselga J, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Science Translational Medicine. 7: 283ra51. PMID 25877889 DOI: 10.1126/Scitranslmed.Aaa4442 |
0.333 |
|
| 2015 |
Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, Baselga J, Rix U, Kubicek S, et al. Targeting a cell state common to triple-negative breast cancers. Molecular Systems Biology. 11: 789. PMID 25699542 DOI: 10.15252/msb.20145664 |
0.385 |
|
| 2015 |
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England Journal of Medicine. 372: 724-34. PMID 25693012 DOI: 10.1056/NEJMoa1413513 |
0.334 |
|
| 2015 |
Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, ... ... Baselga J, et al. PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1334-9. PMID 25559818 DOI: 10.1200/JCO.2014.55.2158 |
0.401 |
|
| 2015 |
Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, ... ... Baselga J, et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 569-76. PMID 25467182 DOI: 10.1158/1078-0432.CCR-14-1824 |
0.347 |
|
| 2014 |
Rodon J, Carducci MA, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, ... ... Baselga J, et al. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 553-60. PMID 25424852 DOI: 10.1158/1078-0432.CCR-14-1380 |
0.31 |
|
| 2014 |
Baselga J, Cortés J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. Biomarker Analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer Journal of Clinical Oncology. 32: 3753-3761. PMID 25332247 DOI: 10.1200/JCO.2013.54.5384 |
0.369 |
|
| 2014 |
Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Cortés J, Kiger C, Germa C, Wang K, Martin M, Baselga J, Kim SB. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3626-33. PMID 25287822 DOI: 10.1200/JCO.2014.56.3809 |
0.348 |
|
| 2014 |
Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. Journal of the National Cancer Institute. 106. PMID 25139534 DOI: 10.1093/Jnci/Dju152 |
0.365 |
|
| 2014 |
de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, ... ... Baselga J, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. The Lancet. Oncology. 15: 1137-46. PMID 25130998 DOI: 10.1016/S1470-2045(14)70320-1 |
0.309 |
|
| 2014 |
Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, ... ... Baselga J, et al. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Molecular Cancer. 13: 141. PMID 24894453 DOI: 10.1186/1476-4598-13-141 |
0.314 |
|
| 2014 |
Swain SM, Im YH, Im SA, Chan V, Miles D, Knott A, Clark E, Ross G, Baselga J. Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. The Oncologist. 19: 693-701. PMID 24869931 DOI: 10.1634/theoncologist.2014-0033 |
0.36 |
|
| 2014 |
Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, ... ... Baselga J, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Science Signaling. 7: ra29. PMID 24667376 DOI: 10.1126/Scisignal.2005125 |
0.356 |
|
| 2014 |
Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, ... ... Baselga J, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. The Lancet. Oncology. 15: 640-7. PMID 24657003 DOI: 10.1016/S1470-2045(14)70080-4 |
0.338 |
|
| 2014 |
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Di Tomaso E, Sternberg DW, Massacesi C, Hirawat S, ... ... Baselga J, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1935-45. PMID 24470511 DOI: 10.1158/1078-0432.Ccr-13-1070 |
0.359 |
|
| 2014 |
Bardia A, Baselga J. Neoadjuvant therapy as a platform for drug development and approval in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6360-70. PMID 24298066 DOI: 10.1158/1078-0432.CCR-13-0916 |
0.307 |
|
| 2014 |
Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galván P, Sapino A, Aglietta M, Baselga J, Scaltriti M. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. Molecular Oncology. 8: 20-6. PMID 24075779 DOI: 10.1016/j.molonc.2013.08.013 |
0.317 |
|
| 2013 |
Vahdat LT, Vrdoljak E, Gómez H, Li RK, Bosserman L, Sparano JA, Baselga J, Mukhopadhyay P, Valero V. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Journal of Geriatric Oncology. 4: 346-52. PMID 24472478 DOI: 10.1016/j.jgo.2013.07.006 |
0.313 |
|
| 2013 |
Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clinical Breast Cancer. 13: 421-432.e8. PMID 24267730 DOI: 10.1016/j.clbc.2013.08.011 |
0.34 |
|
| 2013 |
Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Advances in Therapy. 30: 870-84. PMID 24158787 DOI: 10.1007/s12325-013-0060-1 |
0.373 |
|
| 2013 |
Azim HA, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, Baselga J, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, et al. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial. Breast (Edinburgh, Scotland). 22: 1060-5. PMID 24060577 DOI: 10.1016/j.breast.2013.08.014 |
0.353 |
|
| 2013 |
Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernández-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, ... Baselga J, et al. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discovery. 3: 1238-44. PMID 23950206 DOI: 10.1158/2159-8290.CD-13-0132 |
0.31 |
|
| 2013 |
Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, ... ... Baselga J, et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Science Translational Medicine. 5: 196ra99. PMID 23903756 DOI: 10.1126/Scitranslmed.3005747 |
0.396 |
|
| 2013 |
Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, ... Baselga J, et al. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. European Journal of Cancer (Oxford, England : 1990). 49: 2621-32. PMID 23735704 DOI: 10.1016/j.ejca.2013.04.011 |
0.382 |
|
| 2013 |
Baselga J, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2586-92. PMID 23733761 DOI: 10.1200/JCO.2012.46.2408 |
0.371 |
|
| 2013 |
André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, ... Baselga J, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3693-702. PMID 23658459 DOI: 10.1158/1078-0432.CCR-13-0190 |
0.38 |
|
| 2013 |
Serra V, Eichhorn PJ, GarcÃa-GarcÃa C, Ibrahim YH, Prudkin L, Sánchez G, RodrÃguez O, Antón P, Parra JL, Marlow S, Scaltriti M, Pérez-Garcia J, Prat A, Arribas J, Hahn WC, ... ... Baselga J, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. The Journal of Clinical Investigation. 123: 2551-63. PMID 23635776 DOI: 10.1172/Jci66343 |
0.388 |
|
| 2013 |
Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology. 14: 461-71. PMID 23602601 DOI: 10.1016/S1470-2045(13)70130-X |
0.324 |
|
| 2013 |
Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, Rodenas E, Hudis C, O'Shaughnessy J, Baselga J. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Research and Treatment. 139: 107-13. PMID 23580070 DOI: 10.1007/s10549-013-2510-5 |
0.34 |
|
| 2013 |
Prat A, Baselga J. Dual Human Epidermal Growth Factor Receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: One more step toward chemotherapy-free therapy Journal of Clinical Oncology. 31: 1703-1706. PMID 23569319 DOI: 10.1200/JCO.2012.48.4998 |
0.333 |
|
| 2013 |
Burris HA, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, et al. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 119: 1908-15. PMID 23504821 DOI: 10.1002/cncr.28010 |
0.309 |
|
| 2013 |
Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, Baselga J. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. The Oncologist. 18: 257-64. PMID 23475636 DOI: 10.1634/theoncologist.2012-0448 |
0.331 |
|
| 2013 |
Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nature Reviews. Clinical Oncology. 10: 191-210. PMID 23459626 DOI: 10.1038/nrclinonc.2013.29 |
0.367 |
|
| 2013 |
Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, ... Baselga J, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (New York, N.Y.). 339: 580-4. PMID 23372014 DOI: 10.1126/Science.1228522 |
0.306 |
|
| 2013 |
Loi S, Michiels S, Baselga J, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ, Sotiriou C. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. Plos One. 8: e53292. PMID 23301057 DOI: 10.1371/journal.pone.0053292 |
0.391 |
|
| 2013 |
Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, et al. Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. Cancer Research. 73: 450-8. PMID 23288917 DOI: 10.1158/0008-5472.CAN-12-2301 |
0.325 |
|
| 2012 |
Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, ... ... Baselga J, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discovery. 2: 1036-47. PMID 22915752 DOI: 10.1158/2159-8290.Cd-11-0348 |
0.388 |
|
| 2012 |
Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discovery. 2: 1048-63. PMID 22915751 DOI: 10.1158/2159-8290.Cd-11-0336 |
0.341 |
|
| 2012 |
Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, ... ... Baselga J, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 486: 405-9. PMID 22722202 DOI: 10.1038/Nature11154 |
0.383 |
|
| 2012 |
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2585-92. PMID 22689807 DOI: 10.1200/JCO.2011.35.6725 |
0.351 |
|
| 2012 |
Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, ... ... Baselga J, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 483: 570-5. PMID 22460902 DOI: 10.1038/Nature11005 |
0.323 |
|
| 2012 |
Metzger-Filho O, Tutt A, De Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M. Dissecting the heterogeneity of triple-negative breast cancer Journal of Clinical Oncology. 30: 1879-1887. PMID 22454417 DOI: 10.1200/JCO.2011.38.2010 |
0.313 |
|
| 2012 |
Baselga J, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Durán MÁ, Hoff PM, Espié M, et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1484-91. PMID 22412143 DOI: 10.1200/JCO.2011.36.7771 |
0.396 |
|
| 2012 |
GarcÃa-GarcÃa C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2603-12. PMID 22407832 DOI: 10.1158/1078-0432.Ccr-11-2750 |
0.367 |
|
| 2012 |
Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, ... ... Baselga J, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1594-600. PMID 22393084 DOI: 10.1200/JCO.2011.37.4207 |
0.376 |
|
| 2012 |
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 379: 633-40. PMID 22257673 DOI: 10.1016/S0140-6736(11)61847-3 |
0.315 |
|
| 2012 |
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer New England Journal of Medicine. 366: 520-529. PMID 22149876 DOI: 10.1056/NEJMoa1109653 |
0.368 |
|
| 2012 |
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England Journal of Medicine. 366: 109-19. PMID 22149875 DOI: 10.1056/NEJMoa1113216 |
0.363 |
|
| 2011 |
Cantley LC, Baselga J. The era of cancer discovery. Cancer Discovery. 1: 1. PMID 22586302 DOI: 10.1158/2159-8274.Cd-11-0049 |
0.316 |
|
| 2011 |
Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, ... ... Baselga J, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discovery. 1: 352-65. PMID 22145099 DOI: 10.1158/2159-8290.Cd-11-0106 |
0.335 |
|
| 2011 |
Higgins MJ, Baselga J. Targeted therapies for breast cancer Journal of Clinical Investigation. 121: 3797-3803. PMID 21965336 DOI: 10.1172/JCI57152 |
0.373 |
|
| 2011 |
Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Research : Bcr. 13: R54. PMID 21600050 DOI: 10.1186/Bcr2888 |
0.341 |
|
| 2011 |
Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, Slocum KL, West KA, Rodriguez V, Prudkin L, Jimenez J, Aura C, Baselga J. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer. Molecular Cancer Therapeutics. 10: 817-24. PMID 21383049 DOI: 10.1158/1535-7163.MCT-10-0966 |
0.353 |
|
| 2011 |
Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet. Oncology. 12: 236-44. PMID 21354370 DOI: 10.1016/S1470-2045(11)70033-X |
0.306 |
|
| 2011 |
Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Research. 71: 1515-9. PMID 21343397 DOI: 10.1158/0008-5472.CAN-10-3795 |
0.319 |
|
| 2011 |
Higgins MJ, Baselga J. Breast cancer in 2010: Novel targets and therapies for a personalized approach Nature Reviews Clinical Oncology. 8: 65-66. PMID 21278769 DOI: 10.1038/nrclinonc.2010.217 |
0.303 |
|
| 2011 |
Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. The Oncologist. 12-9. PMID 21278436 DOI: 10.1634/theoncologist.2011-S1-12 |
0.368 |
|
| 2011 |
Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. Clinical Breast Cancer. 10: 489-91. PMID 21147694 DOI: 10.3816/CBC.2010.n.065 |
0.404 |
|
| 2010 |
Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 351-4. PMID 21172881 DOI: 10.1200/JCO.2010.31.6679 |
0.331 |
|
| 2010 |
Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón Y Cajal S, Baselga J, Arribas J. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Research. 70: 8537-46. PMID 20978202 DOI: 10.1158/0008-5472.CAN-10-1701 |
0.31 |
|
| 2010 |
Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, ... ... Baselga J, et al. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 2688-95. PMID 20406840 DOI: 10.1158/1078-0432.CCR-09-3407 |
0.336 |
|
| 2010 |
Eichhorn PJ, Baselga J. HER2 signatures in breast cancer: ready to go to print? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1809-10. PMID 20231675 DOI: 10.1200/JCO.2009.26.7146 |
0.32 |
|
| 2010 |
Di Cosimo S, Baselga J. Management of breast cancer with targeted agents: importance of heterogeneity. [corrected]. Nature Reviews. Clinical Oncology. 7: 139-47. PMID 20125090 DOI: 10.1038/nrclinonc.2009.234 |
0.422 |
|
| 2010 |
Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1124-30. PMID 20124187 DOI: 10.1200/JCO.2008.21.4437 |
0.361 |
|
| 2010 |
Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1131-7. PMID 20124183 DOI: 10.1200/JCO.2009.24.1661 |
0.357 |
|
| 2010 |
Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1138-44. PMID 20124182 DOI: 10.1200/JCO.2009.24.2024 |
0.396 |
|
| 2010 |
Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, ... ... Baselga J, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet (London, England). 375: 377-84. PMID 20113825 DOI: 10.1016/S0140-6736(09)61964-4 |
0.322 |
|
| 2010 |
Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, ... ... Baselga J, et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Research and Treatment. 119: 379-90. PMID 19844788 DOI: 10.1007/s10549-009-0575-y |
0.32 |
|
| 2009 |
Di Cosimo S, Baselga J. Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5017-9. PMID 19671849 DOI: 10.1158/1078-0432.CCR-09-1173 |
0.346 |
|
| 2009 |
Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews. Cancer. 9: 463-75. PMID 19536107 DOI: 10.1038/nrc2656 |
0.307 |
|
| 2009 |
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2630-7. PMID 19380449 DOI: 10.1200/JCO.2008.18.8391 |
0.358 |
|
| 2009 |
Lennon S, Barton C, Banken L, Gianni L, Marty M, Baselga J, Leyland-Jones B. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1685-93. PMID 19255335 DOI: 10.1200/JCO.2008.16.8351 |
0.355 |
|
| 2009 |
Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 526-34. PMID 19075286 DOI: 10.1200/JCO.2007.14.2646 |
0.322 |
|
| 2008 |
Di Cosimo S, Baselga J. Targeted therapies in breast cancer: where are we now? European Journal of Cancer (Oxford, England : 1990). 44: 2781-90. PMID 19013786 DOI: 10.1016/j.ejca.2008.09.026 |
0.372 |
|
| 2008 |
Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Research. 68: 9221-30. PMID 19010894 DOI: 10.1158/0008-5472.CAN-08-1740 |
0.32 |
|
| 2008 |
Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Research. 68: 8022-30. PMID 18829560 DOI: 10.1158/0008-5472.CAN-08-1385 |
0.366 |
|
| 2008 |
Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer Journal of Clinical Investigation. 118: 3065-3074. PMID 18725988 DOI: 10.1172/Jci34739 |
0.314 |
|
| 2008 |
Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 Nature Clinical Practice Oncology. 5: 531-542. PMID 18607391 DOI: 10.1038/ncponc1179 |
0.384 |
|
| 2008 |
Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, ... Baselga J, et al. Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 215-23. PMID 18172273 DOI: 10.1158/1078-0432.CCR-07-1053 |
0.333 |
|
| 2007 |
Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, Baselga J, Rivera E, Guarneri V, Poulart V, Klimovsky J, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3399-406. PMID 17606975 DOI: 10.1200/JCO.2006.08.9102 |
0.316 |
|
| 2007 |
Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, Baselga J. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute. 99: 628-38. PMID 17440164 DOI: 10.1093/jnci/djk134 |
0.334 |
|
| 2007 |
Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: The epothilones Oncologist. 12: 271-280. PMID 17405891 DOI: 10.1634/theoncologist.12-3-271 |
0.37 |
|
| 2007 |
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (London, England). 369: 29-36. PMID 17208639 DOI: 10.1016/S0140-6736(07)60028-2 |
0.313 |
|
| 2007 |
Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. The Oncologist. 4-12. PMID 16971734 DOI: 10.1634/THEONCOLOGIST.11-90001-4 |
0.317 |
|
| 2006 |
Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Seminars in Oncology. 33: 369-85. PMID 16890793 DOI: 10.1053/j.seminoncol.2006.04.003 |
0.348 |
|
| 2006 |
Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J, Arribas J. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. The Embo Journal. 25: 3234-44. PMID 16794579 DOI: 10.1038/sj.emboj.7601191 |
0.342 |
|
| 2006 |
Baselga J. Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2225-6. PMID 16710019 DOI: 10.1200/JCO.2005.05.3785 |
0.309 |
|
| 2006 |
Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2158-63. PMID 16682734 DOI: 10.1200/JCO.2006.06.5961 |
0.327 |
|
| 2005 |
Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8715-21. PMID 16361558 DOI: 10.1158/1078-0432.CCR-05-0539 |
0.311 |
|
| 2005 |
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine. 353: 1659-72. PMID 16236737 DOI: 10.1056/NEJMoa052306 |
0.353 |
|
| 2005 |
Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, ... ... Baselga J, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8081-92. PMID 16204011 DOI: 10.1200/Jco.2005.02.7078 |
0.304 |
|
| 2005 |
Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5960-72. PMID 16087945 DOI: 10.1200/JCO.2005.06.150 |
0.303 |
|
| 2005 |
Baselga J, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero JM, Koehler MT, Rojo F. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5323-33. PMID 15939921 DOI: 10.1200/JCO.2005.08.326 |
0.371 |
|
| 2005 |
Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, Baselga J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3369-76. PMID 15867237 DOI: 10.1158/1078-0432.CCR-04-1923 |
0.326 |
|
| 2005 |
Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2445-59. PMID 15753456 DOI: 10.1200/Jco.2005.11.890 |
0.315 |
|
| 2005 |
Herbst RS, Fukuoka M, Baselga J. Gefitinib--a novel targeted approach to treating cancer. Nature Reviews. Cancer. 4: 956-65. PMID 15573117 DOI: 10.1038/nrc1506 |
0.302 |
|
| 2004 |
Baselga J, Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. Future options with trastuzumab for primary systemic and adjuvant therapy. Seminars in Oncology. 31: 51-7. PMID 15490375 DOI: 10.1053/J.SEMINONCOL.2004.07.022 |
0.358 |
|
| 2004 |
Yarden Y, Baselga J, Miles D. Molecular approach to breast cancer treatment. Seminars in Oncology. 31: 6-13. PMID 15490369 DOI: 10.1053/J.Seminoncol.2004.07.016 |
0.384 |
|
| 2004 |
Arteaga CL, Baselga J. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell. 5: 525-31. PMID 15193255 DOI: 10.1016/J.Ccr.2004.05.028 |
0.329 |
|
| 2004 |
Bianchi G, Albanell J, Eiermann W, Vitali G, Borquez D, Viganò L, Molina R, Raab G, Locatelli A, Vanhauwere B, Gianni L, Baselga J. Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5944-51. PMID 14676119 |
0.344 |
|
| 2004 |
Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, Baselga J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1274-83. PMID 12684395 |
0.351 |
|
| 2003 |
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2787-99. PMID 12860957 DOI: 10.1200/JCO.2003.01.504 |
0.354 |
|
| 2003 |
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, ... ... Baselga J, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 2040-8. PMID 12796366 |
0.305 |
|
| 2003 |
Baselga J, Albanell J. Epithelial growth factor receptor interacting agents. Hematology/Oncology Clinics of North America. 16: 1041-63. PMID 12512382 DOI: 10.1016/s0889-8588(02)00055-2 |
0.309 |
|
| 2002 |
Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 3815-25. PMID 12228201 DOI: 10.1200/JCO.2002.03.038 |
0.307 |
|
| 2002 |
Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist. 2-8. PMID 12202782 DOI: 10.1634/theoncologist.7-suppl_4-2 |
0.374 |
|
| 2002 |
Baselga J, Norton L. Focus on breast cancer. Cancer Cell. 1: 319-22. PMID 12086846 DOI: 10.1016/s1535-6108(02)00066-1 |
0.307 |
|
| 2002 |
Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 110-24. PMID 11773160 DOI: 10.1200/JCO.2002.20.1.110 |
0.305 |
|
| Show low-probability matches. |